FDA Widens Scope In Considering Evidence For Off-Label Use
Executive Summary
After much wrangling, the US agency finally clarified its position on what evidence can determine "intended use" of a product – and industry is not happy.
You may also be interested in...
Expert: Off-Label Communications Guidance Provides Clarifications, Flexibility
A draft guidance on communications of off-label uses for medical products indicates “more flexibility and understanding from FDA” says FDA compliance expert Anne Walsh.
Q&A: FDA’s LDT Inaction Catches Veteran Attorney Off-Guard
Industry experts expected the US FDA to swiftly reverse a Trump-administration policy blocking oversight of lab-developed tests. Its inaction has one former agency attorney wondering why.
There’s No Need To Include Off-Label Use In Labeling, FDA Says In Proposed Rule
After concerns from the medtech industry that a 2017 final rule requires sponsors with knowledge of off-label use of their product to add it to their label, the US FDA is proposing to delete the confusing text.